Hormonal
Combining semaglutide with cilofexor or firsocostat improves liver steatosis more than semaglutide monotherapy in patients with NASH and mild-to-moderate fibrosis, without significantly affecting liver stiffness.
For patients with mild-to-moderate NASH fibrosis, adding cilofexor or firsocostat to semaglutide treatment can reduce liver fat more effectively than semaglutide alone. However, this combination does not appear to improve liver stiffness (fibrosis) and involves taking multiple daily medications alongside weekly injections.
Liver steatosis (evaluated by MRI-PDFF) was decreased to a greater grade with all combination treatments... the improvement was statistically significant only in the semaglutide plus firsocostat arm... Treatment with semaglutide plus firsocostat and semaglutide plus cilofexor 30 mg significantly reduced liver steatosis assessed by the controlled attenuation parameter (CAP)... Nevertheless, all these results compared with semaglutide alone, but no differences in liver stiffness measured by magnetic resonance elastography (MRE) were observed between groups at the end of study.
Why this rating
Based on a phase II open-label randomized trial with small sample sizes per group and no placebo control.
Source
Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
Evgenia Koureta et al. · Frontiers in Pharmacology · 2024
DOI 10.3389/fphar.2024.1343587
More from this paper
- Weekly subcutaneous semaglutide (up to 2.4 mg) significantly reduces liver steatosis and liver enzymes in patients with NAFLD/NASH, but does not significantly improve liver fibrosis or achieve NASH resolution compared to placebo in patients with compensated cirrhosis.Good
- Oral semaglutide (up to 14 mg daily) significantly reduces liver steatosis, liver enzymes, and body weight in patients with NAFLD and Type 2 Diabetes, correlating with weight loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →